Despite Utility, NGS Testing for Cancer Often Denied Insurance Coverage
Expanded genomic panel testing was clinically impactful in nearly two-third of patients with high-risk cancer, yet payers reimbursed only...
Despite Utility, NGS Testing for Cancer Often Denied Insurance Coverage
Expanded genomic panel testing was clinically impactful in nearly two-third of patients with high-risk cancer, yet payers reimbursed only...
The cancer care landscape continues to evolve. Not only do oncologists need to stay up to date on the latest treatment options for their patients, but also the age span of the general population is getting...
The cancer care landscape continues to evolve. Not only do oncologists need to stay up to date on the latest treatment options for their patients, but also the age span of the general population is getting...
In a recent “Ask the Board” column on how clinical pathways are growing, Journal of Clinical Pathways editorial advisory board member Ray Page, DO, PhD, FACOI, FASCO, shared his perspective: “As we continue to see...
In a recent “Ask the Board” column on how clinical pathways are growing, Journal of Clinical Pathways editorial advisory board member Ray Page, DO, PhD, FACOI, FASCO, shared his perspective: “As we continue to see...
Medicare’s coverage for genetic testing is based on each test meeting a “reasonable and necessary” criteria. The decision on whether to order the test depends on real-world patient needs and what existing literature...
Medicare’s coverage for genetic testing is based on each test meeting a “reasonable and necessary” criteria. The decision on whether to order the test depends on real-world patient needs and what existing literature...
Abstract: Value Pathways powered by NCCN™ provides oncologists with a list of clinically proven treatment options that support the delivery of high-quality, cost-effective cancer care. We evaluated the economic and...
Abstract: Value Pathways powered by NCCN™ provides oncologists with a list of clinically proven treatment options that support the delivery of high-quality, cost-effective cancer care. We evaluated the economic and...
Abstract: As the cancer care landscape continues to evolve, oncologists must stay up to date on the latest treatment options for their patients while also navigating the administrative complexities of running a...
Abstract: As the cancer care landscape continues to evolve, oncologists must stay up to date on the latest treatment options for their patients while also navigating the administrative complexities of running a...
Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.
Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.
This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.
This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.
In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...
In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...
This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...
This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...
In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.
Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.
In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.
NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.